Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Inflammatory remarks

Blogs General Research

Ponatinib is an anti-cancer drug which has earned some notoriety for its cost (£90,000 per patient per year) and side-effects that were serious enough to temporarily suspend its use.

Illustration of ponatinib in the RIPK2 protein © Dr Peter Canning
Illustration of ponatinib in the RIPK2 protein

But the findings from a recent Cell Chemistry and Biology paper led by the Structural Genomics Consortium suggest that this 'dirty' drug might actually hold the key for coming up with newer, more effective drugs for chronic illnesses such as Crohn's and Inflammatory Bowel Disease.

The Oxford Science Blog asked the first author, Dr Peter Canning (who worked on this study while at the Nuffield Department of Medicine) to explain what they found. 

Read more

Similar stories

COVID-19: does exercising really reduce the risk?

Coronavirus COVID-19 General

Human challenge trial launches to study immune response to COVID-19

Clinical Trials Coronavirus COVID-19 General

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.